NasdaqGS:REGNBiotechs
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Trial Wins And New Research Partnership
Regeneron Pharmaceuticals (REGN) is back in focus after three pipeline updates in quick succession, including early Lynozyfic data in systemic AL amyloidosis, an accelerated EMA review for Otarmeni, and a large research collaboration with Parabilis Medicines.
See our latest analysis for Regeneron Pharmaceuticals.
Despite a series of fresh pipeline and partnership announcements, Regeneron’s share price is down 15% over the past month and 19% over the past quarter, while the 1 year total...